Starting Doses Conservative protocols begin at 0.2-0.25 mg daily, allowing assessment of individual response before increasing dose
Ensuring optimal care for patients with diabetes with neuropathic symptoms involves a stepwise approach initiated by primary care physicians
From injectable peptides for targeted results to convenient oral and topical options, our peptide therapy in San Diego provides multiple delivery methods to suit your lifestyle
10.1016/j.bbr.2020.112919 Summary Keywords retina, ischemia, BPC 157, L-NAME, rats Citation Zlatar M, Kokot A, Vuletic LB, Masnec S, Kralj T, Perisa MM, Barisic I, Radic B, Milanovic K, Drmic D, Seiwerth S and Sikiric P (2021) BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
Read the DSIP research guide